BioNTech's Chief Business Officer tells AFP that the company is "absolutely delighted" by the EU's approval of the vaccine. BioNtech says that thanks to the mRNA technology, it can have a new vaccine ready "in six weeks" if necessary against the mutated strain detected in Britain.
